Saturday, November 28, 2020 3:40:04 PM
I believe that we'll be in a unique position once TLD is issued. I believe a lot of attention will be focused on the company, it wouldn't surprise me to see major media articles and network interviews on the company. That sort of publicity would make the bigger exchanges want to add the company . By that time we'll be in compliance with the share price, but not necessarily the duration that we've had the price for, nor will we have met filing requirements. The question is, will the exchange want us bad enough to waive listing requirement, or will we be told to make our filings in time, and come see them when we meet the requirements.
I certainly can't say, perhaps to some degree it will depend on just how high our share price is. I don't believe $4 will be a problem, but I can't say we'll have double digits immediately, but I would guess that double digit's would be likely to have an exchange make an exception.
For now, I'd like to see the Annual Report and first quarterly for next year, at that point, whether we're fully compliant or not, I think either Nasdaq or NYSE is likely to accept us. I believe it will happen near mid year, and by that time we may have a partner, and DCVax-L will be approaching approval by all four regulators, one or more may actually already approved.
Gary
I certainly can't say, perhaps to some degree it will depend on just how high our share price is. I don't believe $4 will be a problem, but I can't say we'll have double digits immediately, but I would guess that double digit's would be likely to have an exchange make an exception.
For now, I'd like to see the Annual Report and first quarterly for next year, at that point, whether we're fully compliant or not, I think either Nasdaq or NYSE is likely to accept us. I believe it will happen near mid year, and by that time we may have a partner, and DCVax-L will be approaching approval by all four regulators, one or more may actually already approved.
Gary
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
